U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2004
210
Substance Class Protein
Created
by admin
on Sat Dec 16 01:13:57 GMT 2023
Edited
by admin
on Sat Dec 16 01:13:57 GMT 2023
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG4
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
3JB47N2Q2P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NATALIZUMAB
EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
ANTEGREN
Common Name English
NATALIZUMAB [MI]
Common Name English
Natalizumab [WHO-DD]
Common Name English
NATALIZUMAB [PURPLE BOOK CDER]
Common Name English
AN100226M
Code English
natalizumab [INN]
Common Name English
NATALIZUMAB ELAN PHARMA
Brand Name English
NATALIZUMAB [EMA EPAR]
Common Name English
TYSABRI
Brand Name English
NATALIZUMAB [VANDF]
Common Name English
ANTEGRAN
Code English
NATALIZUMAB [MART.]
Common Name English
NATALIZUMAB [USAN]
Common Name English
IMMUNOGLOBULIN G4 (HUMAN-MOUSE MONOCLONAL AN100226 4-CHAIN ANTI-HUMAN INTEGRIN 4), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL AN100226 LIGHT CHAIN, DIMER
Common Name English
NATALIZUMAB [JAN]
Common Name English
IMMUNOGLOBULIN G4 (HUMAN-MOUSE MONOCLONAL AN100226 4-CHAIN ANTI-HUMAN INTEGRIN 4), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL AN100226 LIGHT CHAIN, DIMER
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C20401
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
WHO-ATC L04AA23
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
EMA ASSESSMENT REPORTS TYSABRI (AUTHORIZED: MULTIPLE SCLEROSIS)
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
NDF-RT N0000175774
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
LIVERTOX NBK548623
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
WHO-VATC QL04AA23
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
NDF-RT N0000175775
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
EMA ASSESSMENT REPORTS NATALIZUMAB ELAN PHARMA (REFUSED: CROHN DISEASE)
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
NCI_THESAURUS C129822
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
Code System Code Type Description
SMS_ID
100000089594
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
IUPHAR
6591
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
MERCK INDEX
m7778
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID90920506
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
DRUG CENTRAL
4970
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
CAS
189261-10-7
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
DRUG BANK
DB00108
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
WIKIPEDIA
NATALIZUMAB
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
USAN
II-90
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
RXCUI
354770
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY RxNorm
HSDB
8174
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201607
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
INN
7716
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
MESH
C469407
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
FDA UNII
3JB47N2Q2P
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
LACTMED
Natalizumab
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
NCI_THESAURUS
C77862
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
EVMPD
SUB22282
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
DAILYMED
3JB47N2Q2P
Created by admin on Sat Dec 16 01:13:57 GMT 2023 , Edited by admin on Sat Dec 16 01:13:57 GMT 2023
PRIMARY
From To
1_22 1_96
1_137 3_213
1_150 1_206
1_229 2_229
1_232 2_232
1_264 1_324
1_370 1_428
2_22 2_96
2_137 4_213
2_150 2_206
2_264 2_324
2_370 2_428
3_23 3_88
3_133 3_193
4_23 4_88
4_133 4_193
Related Record Type Details
INTEGRIN ALPHA-4
TARGET -> INHIBITOR
HIGH AFFINITY IMMUNOGLOBULIN GAMMA FC RECEPTOR I
TARGET -> AGONIST
Related Record Type Details
NATALIZUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
Biological Half-life PHARMACOKINETIC
MOL_WEIGHT:NON-GLYCOSYLATED(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966